Zhao Shanshan, Wang Xiaoyin, Wang Yu, Xu Junjie, Zhu Gang, Zhao Chuansheng, Teng Weiyu
Department of Neurology, The First Hospital of China Medical University, Shenyang, China.
Laboratory of AIDS Immunology of Health Ministry, The First Hospital of China Medical University, Shenyang, China.
Epilepsy Behav. 2018 Aug;85:120-128. doi: 10.1016/j.yebeh.2018.04.029. Epub 2018 Jun 22.
Valproate (VPA) is a broad spectrum antiepileptic drug (AED) that is generally used as a first line agent for most idiopathic and symptomatic generalized epilepsies. Many studies have indicated that AEDs cause reproductive endocrine disorders in males, but the exact etiology underpinning these dysfunctions is not clear. This meta-analysis and systematic review was intended to evaluate the effect of VPA on reproductive endocrine function in male patients with epilepsy.
A literature search was performed using electronic databases up to December 2017 for eligible studies. The differences in the levels of the reproductive factors, luteinizing hormone (LH), follicle-stimulating hormone (FSH), sex hormone binding globulin (SHBG), testosterone, dehydroepiandrosterone sulfate (DHEAS), and androstenedione (ADION) in the male patients with epilepsy treated with VPA (treatment group) were compared with the those of the healthy controls (control group) by the use of the Standardized mean difference (SMD) with 95% confidence intervals (CIs).
Six publications with a total of 316 subjects were identified. The result revealed that the levels of FSH (SMD = -1.33, 95% CI: -2.60 to -0.07, P = 0.039) and testosterone (SMD = -0.45, 95% CI: -0.87 to -0.03, P = 0.038) of the treatment group were decreased significantly compared with the healthy controls. There was an increase in the levels of SHBG (SMD = 0.41, 95% CI: -0.21 to 1.03, P = 0.197), DHEAS (SMD = 0.20, 95% CI: -0.06 to 0.45, P = 0.126) and ADION (SMD = 0.73, 95% CI: -0.10 to 1.57, P = 0.086), and a decrease in that of LH(SMD = -0.71, 95% CI: -1.49 to 0.07, P = 0.075) in the male patients with epilepsy treated with VPA, but the differences did not reach statistical significance (P > 0.05).
This meta-analysis indicates that VPA may lead to a significant decrease in the levels of FSH and testosterone and alter the concentrations of LH, DHEAS, SHBG, and ADION to some extent, which might contribute to the reproductive endocrine dysfunction in male patients with epilepsy. It is important for clinical neurologists to be cautious when prescribing VPA to reproductive-aged male patients with epilepsy.
丙戊酸盐(VPA)是一种广谱抗癫痫药物(AED),通常用作大多数特发性和症状性全身性癫痫的一线用药。许多研究表明,抗癫痫药物会导致男性生殖内分泌紊乱,但这些功能障碍的确切病因尚不清楚。本荟萃分析和系统评价旨在评估VPA对男性癫痫患者生殖内分泌功能的影响。
使用电子数据库进行文献检索,检索截至2017年12月的符合条件的研究。通过标准化均数差(SMD)及95%置信区间(CIs),比较接受VPA治疗的男性癫痫患者(治疗组)与健康对照者(对照组)的生殖因子水平差异,这些生殖因子包括黄体生成素(LH)、卵泡刺激素(FSH)、性激素结合球蛋白(SHBG)、睾酮、硫酸脱氢表雄酮(DHEAS)和雄烯二酮(ADION)。
共纳入6篇文献,总计316名受试者。结果显示,治疗组的FSH水平(SMD = -1.33,95% CI:-2.60至-0.07,P = 0.039)和睾酮水平(SMD = -0.45,95% CI:-0.87至-0.03,P = 0.038)与健康对照组相比显著降低。接受VPA治疗的男性癫痫患者的SHBG水平(SMD = 0.41,95% CI:-上标0.21至1.03,P = 0.197)、DHEAS水平(SMD = 0.20,95% CI:-0.06至0.45,P = 0.126)和ADION水平(SMD = 0.73,95% CI:-0.10至1.57,P = 0.086)有所升高,LH水平有所降低(SMD = -0.71,95% CI:-1.49至0.07,P = 0.075),但差异未达到统计学意义(P > 0.05)。
本荟萃分析表明,VPA可能导致FSH和睾酮水平显著降低,并在一定程度上改变LH、DHEAS、SHBG和ADION的浓度,这可能导致男性癫痫患者出现生殖内分泌功能障碍。临床神经科医生在为育龄期男性癫痫患者开具VPA处方时应谨慎,这一点很重要。